At Foundation Medicine, we are strong believers in the power of a community to make change. The sharing of ideas, opinions, stories, and discoveries can lead to new insights and important connections that wouldn’t otherwise be made. The transformation in cancer care is no different. Through Foundation Forward, we hope to create a community where we can support and challenge each other through conversations, discussions and storytelling, and work together to move the field of oncology forward.

Foundation Medicine’s First FDA-Approved Companion Diagnostic May Improve Outcomes for Women with Ovarian Cancer

Today, Foundation Medicine introduced FoundationFocus™ CDxBRCA, our first product to be approved by the U.S. Food and Drug Administration (FDA). This companion diagnostic is intended to aid in identifying women with ovarian cancer for whom treatment with Rubraca™ (rucaparib) tablets, a therapy developed by Clovis Oncology, Inc., is being considered. Rubraca is an FDA-approved monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It belongs to a class of cancer drugs called poly-ADP-ribose polymerase (PARP) inhibitors.

Read More

Helping Blood Cancer Patients of All Ages: Why We’re at ASH 2016

Blood cancers have helped shape the evolution of cancer treatment from the beginning. As early as World War II, the first chemotherapies were developed to help people living with lymphoma.1 Following those early approaches, we’ve experienced a revolution in our understanding of the genomic drivers of hematologic malignancies that has led to the development of a range of new targeted therapies. With recent advances in comprehensive genomic profiling (CGP), we are now poised to further impact the treatment landscape for blood cancers.

Read More

Newly published data support TMB as a predictor for anti-PD-1/PD-L1 response in melanoma

Over 144,000 Americans are expected to be diagnosed with melanoma this year.1 With a 15-20% 5-year survival rate for Stage IV patients, the future is not always optimistic.2 Thankfully, immunotherapy is changing that outlook. For example, one recent study found that an anti-PD-1 therapy doubled the survival rate in advanced melanoma cases.3

Still, immunotherapies may not work for everyone. Read More

Foundation Medicine Joins Forces to Advance Treatment for Patients with Acute Myeloid Leukemia (AML)

At Foundation Medicine, we are dedicated to advancing precision medicine to transform cancer care. And we recognize that collaboration among industry, academia, advocacy and others is essential for accelerating the development of new precision treatment approaches for patients with cancer – – especially those with rare, difficult to treat and advanced stages of cancer.

Today we announce a collaboration with The Leukemia & Lymphoma Society (LLS) and members of the biopharmaceutical community, as we embark on the first-ever blood cancer master trial to advance treatment for Acute Myeloid Leukemia (AML). AML is the most lethal of all blood cancers, resulting in more than 10,000 deaths each year, and has seen few improvements in treatments in more than 40 years.

Read More

Tumor Mutational Burden: A Valuable Addition to the Pathologist’s Toolbox

We picture pathologists behind the scenes, facing a microscope in a lab rather than a patient in a clinic. Although most patients may never even meet one, there may be no specialist more important to ensuring that the cancer treatment team delivers an effective regimen.

For generations, pathologists’ keen eyes and deep knowledge have been valuable sources of information for understanding a tumor. And today, pathologists have access to genomic information as well, making their role more up-front than ever. As we gain insight into how certain genomic alterations relate to treatment response, pathologists have had to become just as adept at interpreting genomic mutations as they are at identifying rare types of cancer.
Read More

Adding a Personal Touch to the Management of Individuals Living with Blood Cancer

The past half century has witnessed an impressive understanding of cancer in general, and the cancer genome in particular, not just in hematological malignancies, but in diverse cancers. We also firmly recognize the relationship between the cancer cell and its normal tissue microenvironment, and the interplay between this microenvironment and the immune system and the broader concept of inflammation. We now know that about 20 percent of human cancers are related to chronic inflammationi caused by diverse factors, such as autoimmune disease, irritants and infections, such as Helicobacter pylori infections in a subtype of gastric lymphoma. As our understanding of the underlying molecular biology, the cancer ecosystem and cancer-related inflammation improves, we are beginning to appreciate the complexity of the diverse processes and their profound effects on the tissue microenvironment and the malignant clone.

Read More